Latitude (LPI) has initiated two new collaboration studies for its Phospholipid Gel (PG) Depot drug delivery platform.
The company said that the new studies bring the total to seven feasibility/license agreements, that are applying the PG Depot to deliver small molecules, peptides, and proteins for pain, metabolic disease, anti-bacterial, and cardiovascular applications.
Andrew Chen, president of LPI, said: “Our newest feasibility studies represent a growing validation of our PG Depot technology. Like our ongoing collaborations, the new programs aim to transform a cumbersome routine of multiple injections each day into a convenient once-daily or once-weekly format.”
“Both pharma and biotech companies definitely see high value in simplifying parenteral drug administration and extending or resurrecting IP protection through novel delivery technology. The protein-friendly nature of the PG Depot will create many opportunities to convert biologics from daily to weekly injections,” he added.
